BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22527019)

  • 1. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.
    Eloy C; Santos J; Cameselle-Teijeiro J; Soares P; Sobrinho-Simões M
    Virchows Arch; 2012 Jun; 460(6):587-600. PubMed ID: 22527019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.
    Eloy C; Santos J; Soares P; Sobrinho-Simões M
    Virchows Arch; 2011 Sep; 459(3):265-76. PubMed ID: 21796448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma.
    Eloy C; Santos J; Soares P; Sobrinho-Simões M
    Virchows Arch; 2011 Dec; 459(6):595-605. PubMed ID: 22081104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.
    Garcia-Rendueles AR; Rodrigues JS; Garcia-Rendueles ME; Suarez-Fariña M; Perez-Romero S; Barreiro F; Bernabeu I; Rodriguez-Garcia J; Fugazzola L; Sakai T; Liu F; Cameselle-Teijeiro J; Bravo SB; Alvarez CV
    Oncogene; 2017 Feb; 36(5):652-666. PubMed ID: 27452523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.
    Knauf JA; Sartor MA; Medvedovic M; Lundsmith E; Ryder M; Salzano M; Nikiforov YE; Giordano TJ; Ghossein RA; Fagin JA
    Oncogene; 2011 Jul; 30(28):3153-62. PubMed ID: 21383698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
    Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
    Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
    [No Abstract]   [Full Text] [Related]  

  • 8. Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma.
    Min WP; Wei XF
    Auris Nasus Larynx; 2021 Jun; 48(3):487-495. PubMed ID: 33077306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.
    Winer DA; Winer S; Rotstein L; Asa SL; Mete O
    Endocr Pathol; 2012 Dec; 23(4):254-9. PubMed ID: 22847364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells.
    Matsuo SE; Leoni SG; Colquhoun A; Kimura ET
    J Endocrinol; 2006 Jul; 190(1):141-50. PubMed ID: 16837618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
    Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
    Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
    Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
    Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.
    Ricarte-Filho J; Ganly I; Rivera M; Katabi N; Fu W; Shaha A; Tuttle RM; Fagin JA; Ghossein R
    Thyroid; 2012 Jun; 22(6):575-84. PubMed ID: 22471242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
    Walts AE; Mirocha JM; Bose S
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
    Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.